To treat Grown ups with relapsed or refractory a number of myeloma which have acquired at the least four prior therapies This notification is not obligatory; even so, the FDA strongly encourages manufacturers to Call the company and Adhere to the obtainable treatments for our oversight of GRAS conclusions https://proleviate.com/